Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 4/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | TAF1 | P21675 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178948 | 0.77 | TNF (0.53) | IMPDH2IMPDH1CHEK1TNFRIPK1 | |
| SCHEMBL30687262 | 0.77 | TNF (0.44) | IMPDH2IMPDH1CHEK1TNFRIPK1 | |
| SCHEMBL29066876 | 0.73 | IMPDH2 (0.36) | IMPDH2IMPDH1CHEK1TNFRIPK1 | |
| SCHEMBL20157532 | 0.73 | IMPDH2 (0.36) | IMPDH2IMPDH1CHEK1TNFRIPK1 | |
| SCHEMBL15741308 | 0.73 | TNF (0.42) | TNFRIPK1PIM3AHRCYP2A6 | |
| SCHEMBL1420318 | 0.72 | AHR (0.50) | IMPDH2IMPDH1DYRK1AAHRBRD4 | |
| SCHEMBL29361477 | 0.72 | AHR (0.50) | IMPDH2IMPDH1DYRK1AAHRBRD4 | |
| SCHEMBL19611745 | 0.72 | AHR (0.46) | IMPDH2IMPDH1CHEK1RIPK1DYRK1A | |
| SCHEMBL25871527 | 0.72 | CHEK1 (0.43) | IMPDH2IMPDH1CHEK1TNFRIPK1 | |
| Hydrochloric Acid SCHEMBL29363603 | 0.71 | AHR (0.48) | IMPDH2IMPDH1DYRK1AAHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | MEDIC LIFE SCIENCES, INC. | 2024-02-01 | — | — | US | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023227125-A1 | NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4229038-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210403495-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2021-12-30 | — | — | US | disclosed |
| US-20210401859-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-12-30 | — | — | US | disclosed |
| CN-113677346-A | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3873477-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873462-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113226306-A | Methods of treating cancer in a patient identified by a biomarker using a non-covalent inhibitor of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| EP-3484871-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018013867-A1 | INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7) | MARINEAU JASON J (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | CDK7, CDK6, CDK9 | IMPDH2 2104/4885IMPDH1 1778/4885CHEK1 94/4885 |
| US-20240034742-A1 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | CDK7, CCNI, CDK17 | IMPDH2 2175/4885IMPDH1 1640/4885CHEK1 63/4885 |
| US-20210403495-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK1, CDK17 | IMPDH2 3271/4885IMPDH1 2929/4885CHEK1 66/4885 |
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | IMPDH2 4453/4885IMPDH1 4261/4885CHEK1 158/4885 |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | IMPDH2 3271/4885IMPDH1 2929/4885CHEK1 66/4885 |
| US-12240869-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | IMPDH2 3271/4885IMPDH1 2929/4885CHEK1 66/4885 |
| US-20260035393-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNI | IMPDH2 2960/4885IMPDH1 2886/4885CHEK1 70/4885 |
| US-20210401859-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK4, RB1 | IMPDH2 2602/4885IMPDH1 2827/4885CHEK1 47/4885 |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | CDK7, CDK1, CDK17 | IMPDH2 3271/4885IMPDH1 2929/4885CHEK1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.